|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.01.26 - 14:09
|
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) (Business Wire)
|
|
|
OLANZAPINE LAI: EU Submission Expected in Q2 2026MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and full‑year 2025 results:
About UZEDY®
2025 net sales reached $191 million, including $55 million in the fourth quarter
Teva's initial 2026 net sales outlook is in the range of $250 - $280 million
Medincell receives mid‑to high‑single-digit royalties on UZEDY® net sales and is eligible for up to $105 million in commercial milestone payments, subject to the achievement of annual sales thresholds.
About OLANZAPINE LAI
Olanzapine Long-Acting Injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation for a broad population of patients living with schizophrenia.1
Submission of Olanzapine LAI in the European Union for the treatment of schizophrenia in adults is expected in Q2 2026
Following submission to...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
